CGRP Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

Description

The global CGRP inhibitors market is experiencing a surge in demand due to the rising prevalence of migraines worldwide. These inhibitors, a groundbreaking class of pharmaceuticals, target the calcitonin gene-related peptide (CGRP), a key player in migraine development. By preventing CGRP activity, they significantly reduce the frequency and severity of migraines. With a projected compound annual growth rate (CAGR) of 13.90%, the market is poised to achieve substantial growth, offering targeted and effective solutions that are reshaping migraine management and improving the quality of life for millions globally.

Market Insights

CGRP inhibitors work by modulating the activity of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in migraine pathogenesis. By preventing CGRP from binding to its receptors or blocking its release, these inhibitors significantly reduce migraine frequency and severity. As preventive treatments for chronic migraines, CGRP inhibitors are reshaping the therapeutic Analysis for this debilitating condition.

The global CGRP inhibitors market is set to witness significant growth, driven by advancements in migraine therapeutics and increasing awareness among patients and healthcare providers. With innovative solutions and strategic collaborations, the market players are well-positioned to address the growing demand for effective migraine treatments. As the Analysis evolves, CGRP inhibitors continue to redefine the standards of care in migraine management, offering hope and improved quality of life for millions worldwide.

Key Market Drivers

Rising Migraine Prevalence: The growing global burden of migraines necessitates targeted therapeutic interventions, driving the demand for CGRP inhibitors.
Effectiveness and Precision: The targeted mechanism of CGRP inhibitors offers higher efficacy and better safety profiles compared to traditional treatments, increasing their adoption.
Advancements in Migraine Care: The emergence of CGRP inhibitors underscores a paradigm shift in migraine therapeutics, emphasizing precision medicine and personalized care.
Shifting Treatment Paradigms: Healthcare providers are increasingly favoring preventive migraine treatments, recognizing their long-term benefits for patients and reducing reliance on pain-relief medications.
Growing Awareness Among Patients: Awareness campaigns and educational initiatives have played a pivotal role in informing patients about advanced migraine treatment options, further driving demand for CGRP inhibitors.

Business Opportunities

Combination Therapies: Exploring combination treatments involving CGRP inhibitors and other migraine management modalities presents a promising avenue for innovation and revenue growth.
Strategic Partnerships: Collaborations between pharmaceutical companies, healthcare institutions, and research organizations can enhance awareness, accessibility, and affordability of CGRP inhibitors.
Patient-Centric Solutions: Developing non-invasive and patient-friendly delivery methods, such as nasal sprays, can further expand the market reach.

Regional Analysis

Europe: As the leading region, Europe is driving market growth through strategic healthcare initiatives, a robust regulatory framework, and a strong focus on advanced migraine therapies.
South Asia & Pacific: This region is the fastest-growing market, supported by a rising migraine burden, increased awareness of innovative treatments, and improved healthcare access.
North America: The region's advanced healthcare infrastructure and high adoption rates for innovative therapies position it as a critical market for CGRP inhibitors.

Key Players

Prominent companies in the CGRP inhibitors market include:

Amgen
Novartis
Teva Pharmaceutical Industries Ltd.
Eli Lilly
Lundbeck
Abbvie
Allergan

These organizations are at the forefront of research and development, introducing innovative therapies and expanding their product portfolios to maintain a competitive edge.

Market Segmentation

1. By Molecule:

Small Molecule Large Molecule

2. By Treatment:

Preventive Migraine Treatment Acute Migraine Treatment

3. By Route of Administration:

Oral Nasal Injectables

4. By End-Use:

Hospitals Specialty Clinics Mail Order Pharmacies Retail Pharmacies

5. By Region:

North America Europe Asia Pacific Latin America Middle East & Africa

1. Executive Summary

1.1. Global CGRP Inhibitors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Volume and Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. Covid-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact Of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. Pestle Analysis

3. Production Output and Trade Statistics, 2019 - 2023

3.1. Global CGRP Inhibitors Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2023
- 3.1.1. North America
- 3.1.2. Europe
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East and Africa

4. Price Analysis, 2019 - 2023

4.1. Global Average Price Analysis, by Type, US$ Per Unit, 2019 - 2023
4.2. Prominent Factor Affecting CGRP Inhibitors Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2023

5. Global CGRP Inhibitors Market Outlook, 2019 - 2032

5.1. Global CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 5.1.1. Key Highlights
  - 5.1.1.1. Small Molecule
  - 5.1.1.2. Large Molecule
5.2. Global CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 5.2.1. Key Highlights
  - 5.2.1.1. Preventive Migraine Treatment
  - 5.2.1.2. Acute Migraine Treatment
5.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Nasal
  - 5.3.1.3. Injectables
5.4. Global CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospitals
  - 5.4.1.2. Specialty Clinics
  - 5.4.1.3. Mail Order Pharmacies
  - 5.4.1.4. Retail Pharmacies
5.5. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 5.5.1. Key Highlights
  - 5.5.1.1. North America
  - 5.5.1.2. Europe
  - 5.5.1.3. Asia Pacific
  - 5.5.1.4. Latin America
  - 5.5.1.5. Middle East & Africa

6. North America CGRP Inhibitors Market Outlook, 2019 - 2032

6.1. North America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.1.1. Key Highlights
  - 6.1.1.1. Small Molecule
  - 6.1.1.2. Large Molecule
6.2. North America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.2.1. Key Highlights
  - 6.2.1.1. Preventive Migraine Treatment
  - 6.2.1.2. Acute Migraine Treatment
6.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Nasal
  - 6.3.1.3. Injectables
6.4. North America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospitals
  - 6.4.1.2. Specialty Clinics
  - 6.4.1.3. Mail Order Pharmacies
  - 6.4.1.4. Retail Pharmacies
6.5. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.5.1. Key Highlights
  - 6.5.1.1. U.S. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.2. U.S. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.4. U.S. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.5. Canada CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.6. Canada CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.7. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 6.5.1.8. Canada CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe CGRP Inhibitors Market Outlook, 2019 - 2032

7.1. Europe CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.1.1. Key Highlights
  - 7.1.1.1. Small Molecule
  - 7.1.1.2. Large Molecule
7.2. Europe CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.2.1. Key Highlights
  - 7.2.1.1. Preventive Migraine Treatment
  - 7.2.1.2. Acute Migraine Treatment
7.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Nasal
  - 7.3.1.3. Injectables
7.4. Europe CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospitals
  - 7.4.1.2. Specialty Clinics
  - 7.4.1.3. Mail Order Pharmacies
  - 7.4.1.4. Retail Pharmacies
7.5. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.5.1. Key Highlights
  - 7.5.1.1. Germany CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.2. Germany CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.4. Germany CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.5. U.K. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.6. U.K. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.7. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.8. U.K. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.9. France CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.10. France CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.11. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.12. France CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.13. Italy CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.14. Italy CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.15. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.16. Italy CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.17. Turkey CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.18. Turkey CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.19. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.20. Turkey CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.21. Russia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.22. Russia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.23. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.24. Russia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.25. Rest Of Europe CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.26. Rest Of Europe CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.27. Rest Of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 7.5.1.28. Rest of Europe CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific CGRP Inhibitors Market Outlook, 2019 - 2032

8.1. Asia Pacific CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.1.1. Key Highlights
  - 8.1.1.1. Small Molecule
  - 8.1.1.2. Large Molecule
8.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.2.1. Key Highlights
  - 8.2.1.1. Preventive Migraine Treatment
  - 8.2.1.2. Acute Migraine Treatment
8.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Nasal
  - 8.3.1.3. Injectables
8.4. Asia Pacific CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospitals
  - 8.4.1.2. Specialty Clinics
  - 8.4.1.3. Mail Order Pharmacies
  - 8.4.1.4. Retail Pharmacies
8.5. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.5.1. Key Highlights
  - 8.5.1.1. China CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.2. China CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.4. China CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.5. Japan CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.6. Japan CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.7. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.8. Japan CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.9. South Korea CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.10. South Korea CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.11. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.12. South Korea CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.13. India CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.14. India CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.15. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.16. India CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.17. Southeast Asia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.18. Southeast Asia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.19. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.20. Southeast Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.21. Rest Of Asia Pacific CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.22. Rest Of Asia Pacific CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.23. Rest Of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 8.5.1.24. Rest of Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook, 2019 - 2032

9.1. Latin America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.1.1. Key Highlights
  - 9.1.1.1. Small Molecule
  - 9.1.1.2. Large Molecule
9.2. Latin America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.2.1. Key Highlights
  - 9.2.1.1. Preventive Migraine Treatment
  - 9.2.1.2. Acute Migraine Treatment
9.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.3.1. Key Highlights
  - 9.3.1.1. Oral
  - 9.3.1.2. Nasal
  - 9.3.1.3. Injectables
9.4. Latin America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.4.1. Key Highlights
  - 9.4.1.1. Hospitals
  - 9.4.1.2. Specialty Clinics
  - 9.4.1.3. Mail Order Pharmacies
  - 9.4.1.4. Retail Pharmacies
9.5. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.5.1. Key Highlights
  - 9.5.1.1. Brazil CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.2. Brazil CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.4. Brazil CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.5. Mexico CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.6. Mexico CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.7. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.8. Mexico CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.9. Argentina CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.10. Argentina CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.11. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.12. Argentina CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.13. Rest Of Latin America CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.14. Rest Of Latin America CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.15. Rest Of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 9.5.1.16. Rest of Latin America CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook, 2019 - 2032

10.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.1.1. Key Highlights
  - 10.1.1.1. Small Molecule
  - 10.1.1.2. Large Molecule
10.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.2.1. Key Highlights
  - 10.2.1.1. Preventive Migraine Treatment
  - 10.2.1.2. Acute Migraine Treatment
10.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.3.1. Key Highlights
  - 10.3.1.1. Oral
  - 10.3.1.2. Nasal
  - 10.3.1.3. Injectables
10.4. Middle East & Africa CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.4.1. Key Highlights
  - 10.4.1.1. Hospitals
  - 10.4.1.2. Specialty Clinics
  - 10.4.1.3. Mail Order Pharmacies
  - 10.4.1.4. Retail Pharmacies
10.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.5.1. Key Highlights
  - 10.5.1.1. GCC CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.2. GCC CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.4. GCC CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.5. South Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.6. South Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.7. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.8. South Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.9. Egypt CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.10. Egypt CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.11. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.12. Egypt CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.13. Nigeria CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.14. Nigeria CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.15. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.16. Nigeria CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.17. Rest Of Middle East & Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.18. Rest Of Middle East & Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.19. Rest Of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
  - 10.5.1.20. Rest of Middle East & Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
- 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

11.1. By Route of Administration Vs by Treatment Heat Map
11.2. Manufacturer Vs by Treatment Heatmap
11.3. Company Market Share Analysis, 2022
11.4. Competitive Dashboard
11.5. Company Profiles
- 11.5.1. Amgen
  - 11.5.1.1. Company Overview
  - 11.5.1.2. Type Portfolio
  - 11.5.1.3. Financial Overview
  - 11.5.1.4. Business Strategies and Development
- 11.5.2. Novartis
  - 11.5.2.1. Company Overview
  - 11.5.2.2. Type Portfolio
  - 11.5.2.3. Financial Overview
  - 11.5.2.4. Business Strategies and Development
- 11.5.3. Teva Pharmaceutical Industries Ltd.
  - 11.5.3.1. Company Overview
  - 11.5.3.2. Type Portfolio
  - 11.5.3.3. Financial Overview
  - 11.5.3.4. Business Strategies and Development
- 11.5.4. Eli Lilly
  - 11.5.4.1. Company Overview
  - 11.5.4.2. Type Portfolio
  - 11.5.4.3. Financial Overview
  - 11.5.4.4. Business Strategies and Development
- 11.5.5. Lundbeck
  - 11.5.5.1. Company Overview
  - 11.5.5.2. Type Portfolio
  - 11.5.5.3. Financial Overview
  - 11.5.5.4. Business Strategies and Development
- 11.5.6. Abbvie
  - 11.5.6.1. Company Overview
  - 11.5.6.2. Type Portfolio
  - 11.5.6.3. Financial Overview
  - 11.5.6.4. Business Strategies and Development
- 11.5.7. Allergan
  - 11.5.7.1. Company Overview
  - 11.5.7.2. Type Portfolio
  - 11.5.7.3. Financial Overview
  - 11.5.7.4. Business Strategies and Development

12. Appendix

12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms And Abbreviations